A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Refractory Partial Seizures (Protocol 333369-EPY-2003 [Double-blind] and Protocol 333369-EPY-2006 [Open-label Extension])
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Carisbamate (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Registrational
- Sponsors SK Life Science
- 08 Dec 2009 Results presented at the Annual Meeting of the American Epilepsy Society.
- 08 Dec 2009 Changed actual number of patients from 500 to 537 according to an abstract from the Annual Meeting of the American Epilepsy Society.
- 17 Oct 2006 Status change